Amneal Pharmaceuticals (AMRX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
$17.25+1.17%
Close 2026-09-09 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
Broken: Primary pillar broken — Cash from operations improves from negative $26.7 million: OCF -$26.7M vs $0M.
Amneal grows revenue about 6% a year to $3.1 billion in 2026. Profit rose to $142 million in Q1 2026. The company expands by buying Kashiv BioSciences. This supports steady growth and better profits.
Cash flow from operations fell to negative $27 million in Q1 2026. This shows trouble turning profits into cash. Growth may slow if cash issues continue.
The price is about 13% below our fair value near $20. Analysts expect about 6% revenue growth. We agree with these views.
Breaks if: Cash flow remains negative below zero over next 4 quarters
Breaks if: Acquisition fails or does not contribute to growth by FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on growth through mergers and acquisitions. The current thesis state is intact, as recent financial performance has been strong and management is executing on its priorities.
The market seems to expect a moderate level of performance, with a slight gap in expectations. Valuation is neutral compared to peers, indicating that while there is some premium, it is not excessive.
Fundamentals are likely to improve as management continues to focus on profitability and revenue growth. Recent results show a positive trend, but there is a moderate risk of missing future guidance, which could impact sentiment.
The thesis hinges on management's ability to maintain guidance and execute on its M&A strategy. Additionally, broader sector performance and economic indicators, such as job reports, will influence AMRX's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company raised its full-year 2026 financial guidance. It also improved operating income with record revenue. There are no current threats to this positive outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Complete acquisition of Kashiv BioSciences to establish a global biosimilars platform and diversify growth into biosimilars.
Stated as a priority in 3 disclosures including 2026-Q2 and two 2026-08 filings. Management completed the acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars platform to capitalize on a $300B+ global biologics loss-of-exclusivity wave. This strategic M&A expands Amneal's growth profile into the 2030s. The transaction includes $375M cash, $375M equity, and up to $350M in milestone payments. The trajectory is delivering with the acquisition completed as planned.
“We are excited about the pending Kashiv transaction, which will establish biosimilars as an important new, durable growth vertical for Amneal.”
Breaks if: Operating income falls below $130 million in Q1 2026
Focus on enhancing operating income through cost management and efficiency improvements.
Breaks if: Revenue falls below $3.0 billion in FY26
Complete acquisition of Kashiv BioSciences to establish a global biosimilars platform and diversify growth into biosimilars.
Stated as a priority in 3 disclosures including 2026-Q2 and two 2026-08 filings. Management completed the acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars platform to capitalize on a $300B+ global biologics loss-of-exclusivity wave. This strategic M&A expands Amneal's growth profile into the 2030s. The transaction includes $375M cash, $375M equity, and up to $350M in milestone payments. The trajectory is delivering with the acquisition completed as planned.
“We are excited about the pending Kashiv transaction, which will establish biosimilars as an important new, durable growth vertical for Amneal.”
Over the next 1 to 3 years, AMRX appears to be on a solid path, but it faces risks that could affect its performance. Not investment advice.